Pill-watching practice may not improve Tuberculosis treatment

Tuberculosis patients who swallow their anti-tuberculosis pills under the watchful gaze of doctors fare just as well as patients trusted to self-medicate, according to a new analysis.

"Do we still need to observe patients taking their pills? Our findings are that's probably not as useful and we could direct resources to other interventions that would be more cost-effective," said study co-author Dr. Tawanda Gumbo, associate professor of medicine at the UT Southwestern Medical Center.

The analysis of past research included 10 studies covering 8,774 TB patients observed to take their pills and 3,708 TB patients who took treatments on their own.

For both groups, the researchers examined whether the bacteria that cause tuberculosis remained after treatment, and whether patients relapsed or developed a drug-resistant form of TB.

The patients did as well on all three counts whether health care workers witnessed them swallowing their anti-TB pills or they were allowed to take the pills on their own, Gumbo's group reports in the journal Clinical Infectious Diseases.

Tuberculosis killed 1.4 million people worldwide in 2011, according to estimates from the World Health Organization. The global target of halving tuberculosis death rates between 1990 and 2015 will likely not be reached in Africa and Europe, WHO officials warn, and the current 630,000 cases of multi-drug resistant TB have alarmed officials.

WHO adopted a system of government-supported infrastructure to ensure standard diagnosis and treatment for TB patients, of which one component is doctor-monitored pill-taking.

Observing patients taking their drugs, a resource-intensive practice, is thought to help patients adhere to their medication regimens that last a minimum of six months. Taking medications irregularly or stopping before the full treatment course is completed can promote the development of drug-resistant TB strains.

Critics of the pill-watching approach say, however, that allowing TB patients to take their own medications is just as effective and costs less, and more attention should be paid to improving the TB treatments themselves.

"Let's take those resources watching patients take their pills and start looking at why patients are failing therapy and drug resistance remains," Gumbo told Reuters Health.

Gumbo proposes personalized TB treatments that move away from a one-pill-fits-all approach. Since people metabolize TB drugs differently, the doses and timing of their medications should be adjusted accordingly.

His group is currently estimating the cost savings and feasibility of a personalized system in a population in South Africa.

"The system would be able to recoup its cost via treating fewer drug-resistant tuberculosis patients," Gumbo said.